<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>The New England Journal of Medicine: Search Results in Cardiology</title>
        <description>The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Cardiology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.</description>
        <link>https://www.nejm.org/action/showPodcastsFeeds</link>
        <generator>NEJM Group</generator>
        <lastBuildDate>Thu, 17 Sep 2026 08:05:38 GMT</lastBuildDate>
        <copyright>2026 NEJM Group</copyright>
        <language>en-us</language>
        <ttl>1440</ttl>
        <atom:link href="https://onesearch-rss.nejmgroup-production.org/specialty/cardiology" rel="self" type="application/rss+xml"/>
        <item>
            <title>Celiac-Artery Dissection</title>
            <description>A 72-year-old man with hypertension, hyperlipidemia, and a stable ascending aortic aneurysm presented with sudden-onset, severe chest pain. CTA of the chest, abdomen, and pelvis showed a celiac-artery dissection.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMicm2605936?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMicm2605936</guid>
            <dc:creator>Akshat Agrawal, Kimberly Foust</dc:creator>
            <dc:date>2026-09-17</dc:date>
            <dc:title>Celiac-Artery Dissection</dc:title>
        </item>
        <item>
            <title>Complete Revascularization Guided by Functional Coronary Angiography in STEMI</title>
            <description>Among patients with ST-segment elevation myocardial infarction and multivessel disease, physiology-guided angiography led to a lower risk of major cardiovascular events than conventional angiography-guided treatment.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2605373?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2605373</guid>
            <dc:creator>Simone Biscaglia, Andrea Erriquez, Iginio Colaiori, Abdul Hakeem, Francesca Mantovani, Mila Menozzi, Marco Barbierato, Manfredi Arioti, Giulia Bugani, Roberto Scarsini, Domenico D’Amario, Luca Donazzan, Alberto Polimeni, Massimo Giordan, Giorgio Benatti, Gabriele Venturi, Marco Ruozzi, Francesco Moretti, Alberto Monello, Elisabetta Moscarella, Francesco Versaci, Jehangir Ali Shah, Vincenzo Guiducci, Caterina Cavazza, Francesco Gallo, Andrea Rubboli, Marco Borgi, Ahsan Ali Lakho, Alessandro Capecchi, Valerio Lanzilotti, Filippo Ottani, Gianni Casella, Antonio Maria Leone, Matteo Tebaldi, Rita Pavasini, Raffaele Piccolo, Jacopo Farina, Donato Martella, Gianluca Campo, the AIR-STEMI Trial Investigators*</dc:creator>
            <dc:date>2026-09-10</dc:date>
            <dc:title>Complete Revascularization Guided by Functional Coronary Angiography in STEMI</dc:title>
        </item>
        <item>
            <title>Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials</title>
            <description>In two placebo-controlled trials, oveporexton improved wakefulness, reduced daytime sleepiness, and lowered the cataplexy rate among patients with narcolepsy type 1. Increased urinary frequency and transient insomnia were common.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2601598?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2601598</guid>
            <dc:creator>Yves Dauvilliers, Emmanuel Mignot, Jakub Antczak, Isabelle Arnulf, Lucie Barateau, Erik Buntinx, Bruce Corser, Alex Iranzo, Ramin Khatami, Gert Jan Lammers, Katharina Lederer, Kristian Bernhard Nilsen, Fabio Pizza, Markus H. Schmidt, Sheila Sivam, Oliver Sum-Ping, Mitsutaka Taniguchi, Shuqin Zhan, Anson Abraham, Alice Cai, Yeting Du, Mark R. Etherton, Helene Faessel, Samuel Hsiao, Harisha Kadali, Elena Koundourakis, Melissa Naylor, Rachel Neuwirth, Tina Olsson, Raquel Rogers, Sarah Sheikh, Shinichiro Tanaka, Philipp von Rosenstiel, Christian von Hehn, Yaming Hang, Baiyun Yao, Rafael del Rio Villegas, Giuseppe Plazzi</dc:creator>
            <dc:date>2026-09-09</dc:date>
            <dc:title>Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials</dc:title>
        </item>
        <item>
            <title>Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism</title>
            <description>Catheter-directed thrombolysis led to a lower risk of death, recurrent pulmonary embolism, or cardiorespiratory decompensation or collapse at 7 days than anticoagulation alone in intermediate-high–risk acute pulmonary embolism.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608012?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608012</guid>
            <dc:creator>Josef Kroupa, Martin Radvan, Jan Mrozek, Martin Sluka, Stepan Jirous, Ota Hlinomaz, Milan Pliva, Jan Pudil, Hana Voberkova, Karolina Bartoskova, Martin Poloczek, Martin Kamenik, Michal Brabec, Eva Lichnerova, Martin Hutyra, Ivo Bernat, Martin Novak, Johana Horakova, Lucie Jelinkova, Tomas Knize, Petr Tousek, Cyril Stechovsky, Filip Varhanik, Zdenek Coufal, Jiri Jarkovsky, Viktor Kocka</dc:creator>
            <dc:date>2026-08-31</dc:date>
            <dc:title>Catheter-Directed Thrombolysis in Intermediate-High–Risk Pulmonary Embolism</dc:title>
        </item>
        <item>
            <title>Immediate Ambulatory Electrocardiographic Monitoring in Syncope</title>
            <description>Among patients with syncope that remained unexplained after evaluation in the ED, immediate initiation of 14-day ECG monitoring did not result in significantly fewer patient-reported syncope episodes at 1 year than standard care.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2605812?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2605812</guid>
            <dc:creator>Matthew J. Reed, Steve Goodacre, Christopher J. Weir, Lynn Dinsmore, Amy Nugent, Titouan Kennel, Christopher C. Lang, Neil R. Grubb, Praveen Thokala, Karen Kilcoyne, Rachel O’Brien, Caroline Blackstock, Shona McDonald, Nicola Freeman, Ellise Clarke, Imad Adamestam, Louise Taylor, the ASPIRED Investigators*</dc:creator>
            <dc:date>2026-08-31</dc:date>
            <dc:title>Immediate Ambulatory Electrocardiographic Monitoring in Syncope</dc:title>
        </item>
        <item>
            <title>Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension</title>
            <description>In pulmonary hypertension associated with left heart disease and heart failure, pulmonary-artery denervation reduced clinical worsening and recurrent heart failure events as compared with guideline-directed medical therapy alone.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2609056?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2609056</guid>
            <dc:creator>Hang Zhang, Qiguang Wang, Ming Liang, Xiang Chen, Wei Zhuang, Biao Cheng, Yue Li, Jieyan Shen, Bin Liu, Caojing Zhang, Gangcheng Zhang, Xinxue Liao, Zhenwen Yang, Ruilin He, Yuquan He, Yunshan Cao, Yan Wang, Dajun Chai, Wei Huang, Xiaoping Peng, Wen Gu, Gregg W. Stone, Yaling Han, Shao-Liang Chen, the PADN-HF-PH Investigators*</dc:creator>
            <dc:date>2026-08-30</dc:date>
            <dc:title>Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension</dc:title>
        </item>
        <item>
            <title>Tricuspid-Valve Intervention in Heart Failure</title>
            <description>In patients with severe tricuspid regurgitation and heart failure, transcatheter tricuspid-valve repair plus medical therapy was superior to medical therapy alone in reducing hospitalizations for heart failure and deaths.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2606934?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2606934</guid>
            <dc:creator>Jörg Hausleiter, Thomas J. Stocker, Tobias Geisler, Philipp Lurz, Wolfgang Rottbauer, Edith Lubos, Niklas Schofer, Christian Frerker, Johanne Frank, Holger Thiele, Rico Osteresch, Volker Rudolph, Alexander Lauten, Erion Xhepa, Jürgen Rothe, Tienush Rassaf, Stephan Baldus, Georg Nickenig, David M. Leistner, Eike Tigges, Victoria Kehl, Mirjam Kessler, Tobias Kister, Tobias Ruf, Muhammed Gerçek, Meinrad Gawaz, Derk Frank, Ingo Eitel, Ralph Stephan von Bardeleben, Daniel Kalbacher, Osama Soliman, Michael Näbauer, Steffen Massberg, the TRIC-I-HF-DZHK24 Investigators*</dc:creator>
            <dc:date>2026-08-30</dc:date>
            <dc:title>Tricuspid-Valve Intervention in Heart Failure</dc:title>
        </item>
        <item>
            <title>Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation</title>
            <description>In patients with severe aortic stenosis and coronary artery disease, a strategy of transcatheter aortic-valve implantation before percutaneous coronary intervention was noninferior to PCI before TAVI for major clinical events at 1 year.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2606924?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2606924</guid>
            <dc:creator>Barbara E. Stähli, Frank Ruschitzka, Dirk Westermann, Axel Linke, Norman Mangner, Nicolas M. Van Mieghem, Rahel Kesterke, Laura Oberholzer, Jürgen Rothe, Constantin von zur Mühlen, Tobias Zeus, Won-Keun Kim, Philipp Lauten, Nikos Werner, Christof Burgdorf, Hannes Alber, P. Christian Schulze, Michael Joner, Jonathan Michel, Alessandro Candreva, Philipp Jakob, Michael Würdinger, Julia Stehli, Alexander Gotschy, Christian Templin, Omer Dzemali, Luise Gaede, Steffen Massberg, Alexander Lauten, Frank van der Kley, Aydan Ewers, Thomas Nestelberger, Mohamed Abdel-Wahab, Giuseppe Musumeci, Sebastian Barth, Michael Hansen, Andreas Mügge, Moritz Seiffert, David M. Leistner, Thomas Cuisset, Steffen Schneider, Adnan Kastrati, Ian Ford, Markus A. Kasel, the TAVI PCI Investigators*</dc:creator>
            <dc:date>2026-08-30</dc:date>
            <dc:title>Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation</dc:title>
        </item>
        <item>
            <title>Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event</title>
            <description>Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608717?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608717</guid>
            <dc:creator>C. Michael Gibson, P. Gabriel Steg, M. Cecilia Bahit, Rasha Al-Lamee, Shamir R. Mehta, Roxana Mehran, Jeffrey I. Weitz, Shinya Goto, Jose Carlos Nicolau, Renato D. Lopes, Junbo Ge, Nebojsa Tasic, Dominick J. Angiolillo, Suzanne J. Baron, Ajay J. Kirtane, Denis Xavier, Satoshi Yasuda, Basil S. Lewis, Duk-Woo Park, Jan H. Cornel, Thomas W. Johnson, Jaroslaw Trebacz, Daniel Duerschmied, Christoph Bode, Bela Merkely, Maria Dorobantu, Dragos Vinereanu, Zuzana Motovska, Hector Bueno, Jose Luis Lopez-Sendon, Gregory Ducrocq, Giuseppe Ambrosio, Lesley Burgess, Allan Bohm, Chern-En Chiang, Joao Morais, Alan Fong, Umit Guray, Jose Luis Leiva-Pons, Pascal Vranckx, Harvey D. White, Sasko Kedev, Marco Valgimigli, Duško Cerovec, Dimitris Tousoulis, Gemma Figtree, Thuong Dung Ho, Rody G. Sy, Morten Bøttcher, Kurt Huber, Rimvydas Slapikas, Andrejs Erglis, Jack Wei Chieh Tan, Christian Pincetti, Karen S. Pieper, Kenneth W. Mahaffey, Carolyn S.P. Lam, S. Claiborne Johnston, Graeme J. Hankey, Jennifer S. Li, Luke Zheng, Ronald Aronson, Danshi Li, Ravi Notani, Philippe Vieira Pires, Thomas J. Povsic, Alistair C. Lindsay, Alexei Plotnikov, Hsiaowei Deng, Elliot S. Barnathan, Robert A. Harrington, the LIBREXIA ACS Committees and Investigators*</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event</dc:title>
        </item>
        <item>
            <title>Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients</title>
            <description>In patients at high risk for ischemic events 12 months after implantation of a drug-eluting stent, clopidogrel monotherapy was noninferior to extended dual antiplatelet therapy for net adverse clinical events.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608533?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608533</guid>
            <dc:creator>Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee, Deok-Kyu Cho, Yun-Hyeong Cho, Sung Gyun Ahn, Kyeong Ho Yun, Ji-Yong Jang, Seunghwan Kim, Yong Hoon Kim, Yong Hwan Park, Sung Uk Kwon, Seung-Ho Hur, Tae Soo Kang, Eun-Seok Shin, Jin Bae Lee, Ki-Hyun Jeon, Ung Kim, Won Ho Kim, Bum-Kee Hong, Sang-Hyup Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Yangsoo Jang, Byeong-Keuk Kim, the A-CLOSE investigators*</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients</dc:title>
        </item>
        <item>
            <title>Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI</title>
            <description>Among patients with STEMI, prasugrel monotherapy initiated before PCI was not noninferior to dual antiplatelet therapy with prasugrel plus aspirin for a composite of death, stroke, or myocardial infarction at 12 months.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2606997?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2606997</guid>
            <dc:creator>Kuniaki Takahashi, Ken Kozuma, Yoshihiro Morino, Kosuke Kashiwabara, Hiromasa Otake, Satoru Suwa, Mamoru Nanasato, Takashi Muramatsu, Hitoshi Anzai, Akihiro Shirakabe, Masashi Yamamoto, Yasuhide Asaumi, Masashi Sakuma, Hideki Okayama, Keisuke Nakabayashi, Nobuhiko Ogata, Kentaro Jujo, Kohei Wakabayashi, Takanori Kusuyama, Yuko Onishi, Kazuhiro Ashida, Yuya Mitsuhashi, Yuji Nishimoto, Seiji Yamazaki, Nehiro Kuriyama, Yuji Ikari, Gaku Nakazawa, the PREMIUM Trial Investigators*</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Aspirin Omission at the Time of Primary Percutaneous Coronary Intervention in STEMI</dc:title>
        </item>
        <item>
            <title>Prasugrel versus Ticagrelor in Acute Coronary Syndromes</title>
            <description>Among patients with acute coronary syndromes undergoing percutaneous coronary intervention, the risk of ischemic events was not lower with a default prasugrel policy than with a default ticagrelor policy.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2609057?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2609057</guid>
            <dc:creator>Elmir Omerovic, Sasha Koul, Jonas Andersson, Johan Pontén, Fredrik Björklund, Robert Kastberg, Mila Sun, Charlotta Ljungman, Ole Fröbert, Kristian Bolin, Kristofer Skoglund, Carl-David Dolata, Mats Birgander, Helena Wikström, Truls Råmunddal, Oskar Angerås, Petur Petursson, David Erlinge, Björn Redfors</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Prasugrel versus Ticagrelor in Acute Coronary Syndromes</dc:title>
        </item>
        <item>
            <title>Prevalence of Silent Atherosclerosis across Adult Life</title>
            <description>Among 16,808 adults without known cardiovascular disease, silent atherosclerosis was present in 57.1%, was detectable in early adulthood, and became more prevalent and extensive with age in a sex-dependent pattern.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2609059?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2609059</guid>
            <dc:creator>Henning Bundgaard, Inés García-Lunar, Klaus F. Kofoed, Rasmus Hasselbalch, Carlos Nicolás Pérez-García, Joakim Bo Kunkel, Frederik Filip Stæger, Fátima Sánchez-Cabo, José J. Fuster, Virginia Mass, Javier Sánchez-González, Maja V. Kragh, Anna K. Ringgaard, Javier Valls-Monzó, Michael Huy Cuong Pham, Ana Devesa, Morten Sejer, Per Sigvardsen, Antonio Quesada, Charlotte Eberhard, Ana García-Álvarez, Lea Marie Pehrson, Álvaro Navarro-Guzmán, Simon Winther, Mathias Sørgaard, Marcos Gámez, Martin Lundsgaard, Cristina Pérez-Herreras, Ruth Frikke-Schmidt, Pedro L. Sánchez, Nikolaj Eldrup, Juan Torres-Macho, Morten Bøttcher, Valentin Fuster, Kasper K. Iversen, Borja Ibanez, the REACT Investigators*</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Prevalence of Silent Atherosclerosis across Adult Life</dc:title>
        </item>
        <item>
            <title>Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain</title>
            <description>In patients with suspected acute coronary syndrome without myocardial infarction, routine CT coronary angiography did not result in a lower incidence of myocardial infarction or death from a cardiac cause than standard care.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608903?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608903</guid>
            <dc:creator>Kuan Ken Lee, Ryan Wereski, David Lowe, Rachel O’Brien, Amy V. Ferry, Anda Bularga, Matthew T.H. Lowry, Caelan Taggart, Giles Roditi, Nick Curzen, Sarojini David, Dirk Felmeden, Randeep Hunjan, Attila Kardos, Liza Keating, Dennis Sandeman, Jason E. Smith, Carl Roobottom, Chris Tuck, Denise Cranley, Praveen Thokala, Steve Goodacre, Titouan Kennel, Catriona Keerie, John Norrie, Michelle C. Williams, David E. Newby, Alasdair J. Gray, Nicholas L. Mills, the TARGET-CTCA Investigators*</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain</dc:title>
        </item>
        <item>
            <title>Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults</title>
            <description>In older adults without cardiovascular disease, treatment with atorvastatin led to a lower risk of major cardiovascular events than placebo at a median of 5.9 years but did not result in longer disability-free survival.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2607314?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2607314</guid>
            <dc:creator>Sophia Zoungas, Rory Wolfe, Chris Moran, Stephen J. Nicholls, Geoffrey C. Cloud, Christopher M. Reid, Andrew M. Τonkin, Lawrence Beilin, Anthony S. Wierzbicki, Trevor T.-J. Chong, Jonathan C. Broder, Andrea J. Curtis, Zachary Flanagan, Ingrid Hopper, Joanne Ryan, Simone Spark, John J. McNeil, Mark R. Nelson, the STAREE Investigators</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults</dc:title>
        </item>
        <item>
            <title>The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome</title>
            <description>Acute coronary syndrome is one of the most common reasons for hospital admission. In the United States alone, it is estimated that there are more than 1 million unique hospitalizations annually that involve a diagnosis of acute coronary syndrome.1 For patients with acute coronary syndromes who are not...</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMe2610678?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMe2610678</guid>
            <dc:creator>Robert A. Byrne</dc:creator>
            <dc:date>2026-08-29</dc:date>
            <dc:title>The Emerging Role of Treatment Policy Implementation Trials in Acute Coronary Syndrome</dc:title>
        </item>
        <item>
            <title>Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy</title>
            <description>In a phase 3 trial of treatment for symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten resulted in a significantly greater change in exercise capacity and patient-reported health status at 36 weeks than placebo.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2603021?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2603021</guid>
            <dc:creator>Ahmad Masri, Martin S. Maron, Ankit Bhatia, Maria Luisa Peña-Peña, Mark V. Sherrid, Estevao Lanna Figueiredo, Michael Arad, Roberto Barriales-Villa, Lubna Choudhury, Brian L. Claggett, Caroline J. Coats, Edileide de Barros Correia, Juan Pablo Costabel, Perry M. Elliott, Jorge E. Silva Enciso, Pablo Garcia-Pavia, Junbo Ge, Sheila M. Hegde, Gregory D. Lewis, Renato D. Lopes, Matthew W. Martinez, Mathew S. Maurer, Zi Michael Miao, Michelle Michels, Sumeet S. Mitter, Jesus E. Pino Moreno, Iacopo Olivotto, Anjali T. Owens, Steen H. Poulsen, Florian Rader, Ethan J. Rowin, P. Christian Schulze, Robert Sepp, Nikhil Sikand, Scott D. Solomon, John A. Spertus, Charles Teale Sr., Xiaoyan Zhao, Punag H. Divanji, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Fady I. Malik, Joel Salazar-Mendiguchía, Amy Wohltman, Shu Zhuo, Carolyn Y. Ho, the ACACIA-HCM Investigators*</dc:creator>
            <dc:date>2026-08-28</dc:date>
            <dc:title>Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy</dc:title>
        </item>
        <item>
            <title>Eplontersen for Transthyretin Amyloid Cardiomyopathy</title>
            <description>Among patients with TTR amyloid cardiomyopathy, eplontersen did not lead to a significantly lower risk of a composite of cardiovascular death and recurrent cardiovascular events than placebo up to 140 weeks.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2608510?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2608510</guid>
            <dc:creator>Marianna Fontana, Ahmad Masri, Scott D. Solomon, Francesco Cappelli, Margot K. Davis, Pablo García-Pavía, Julian D. Gillmore, Mazen Hanna, Laura Obici, Brett W. Sperry, Nobuhiro Tahara, Márcia Waddington-Cruz, Olga Azevedo, Thibaud Damy, Edileide de Barros Correia, Michel G. Khouri, Andriana P. Nikolova, Stefan Störk, Tom Conrad, Qingqing Yang, Brian L. Claggett, Jersey Chen, Gary T. Brice, Sotirios Tsimikas, Mathew S. Maurer, the CARDIO-TTRansform Investigators*</dc:creator>
            <dc:date>2026-08-28</dc:date>
            <dc:title>Eplontersen for Transthyretin Amyloid Cardiomyopathy</dc:title>
        </item>
        <item>
            <title>Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis</title>
            <description>Among adults with endocarditis caused by S. aureus, E. faecalis, or streptococcus species, tailored-duration antibiotic therapy led to 13 more days alive without antibiotics than standard therapy, but with a higher incidence of relapse.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2607887?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2607887</guid>
            <dc:creator>Henning Bundgaard, Mia Pries-Heje, Julie Hjulmand, Rasmus Hasselbalch, Peter Godsk Jørgensen, Søren Fanø, Nana Køber, Christian Tuxen, Nareen Kader, Ekim Seven, Lars Ege Rasmussen, Malene Wienberg, Niels Eske Bruun, Marlene Tofterup, Magnus Rasmussen, Lindsey R. Baden, Ann Woolley, Theis Lange, Jannik Helweg-Larsen, Jonas Agerlund Povlsen, Emil Fosbøl, Claus Moser, Kasper Iversen, the POET II Investigators*</dc:creator>
            <dc:date>2026-08-28</dc:date>
            <dc:title>Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis</dc:title>
        </item>
        <item>
            <title>Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk</title>
            <description>In patients with atrial fibrillation and intermediate stroke risk, direct oral anticoagulation led to a lower risk of stroke, systemic embolism, major bleeding, or death from cardiovascular causes than no anticoagulation.</description>
            <link>https://www.nejm.org/doi/full/10.1056/NEJMoa2607978?rss=searchAndBrowse</link>
            <guid isPermaLink="false">https://www.nejm.org/doi/full/10.1056/NEJMoa2607978</guid>
            <dc:creator>Daehoon Kim, Young Soo Lee, Jaemin Shim, Hee Tae Yu, Junbeom Park, Jin-Kyu Park, Il-Young Oh, Ki-Woon Kang, Eue-Keun Choi, Kyoung-Min Park, Hyoung-Seob Park, Dae-Hyeok Kim, Hyung Wook Park, Jun Kim, Jum-Suk Ko, Dongmin Kim, Jong-Youn Kim, Jin-Bae Kim, Jung-Hoon Sung, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Boyoung Joung, the SINGLE-AF Investigators*</dc:creator>
            <dc:date>2026-08-28</dc:date>
            <dc:title>Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk</dc:title>
        </item>
    </channel>
</rss>